September 12, 2024 – LDEBIO is pleased to announce that its innovative tuberculosis (TB) infection detection product, the AIMTB Mycobacterium Tuberculosis-Specific Cellular Immune Response Detection Kit (Chemiluminescence Method), has successfully obtained the Class III Medical Device Registration Certificate from the National Medical Products Administration (NMPA). This achievement follows the recent certification of the AIMTB (Fluorescence Immunochromatography Method) in early September, further solidifying LDEBIO 's leadership in TB detection technology and marking the completion of its full-platform,full-scenario product portfolio for TB infection detection.
